Phase 2 Trial of Potential Prostate Cancer Vaccine, ProscaVax, Soon to Enroll Early-stage Patients

Phase 2 Trial of Potential Prostate Cancer Vaccine, ProscaVax, Soon to Enroll Early-stage Patients
OncBioMune Pharmaceuticals will soon start a Phase 2 clinical trial of its investigational vaccine ProscaVax in people with early-stage prostate cancer. ProscaVax consists of a combination of the PSA protein (a hallmark of prostate cancer) with the cytokines interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF). [Cytokines are molecules that participate in immune responses.] The study (NCT03579654) intends to assess the safety and efficacy of ProscaVax in about 120 patients with low-risk, localized and untreated prostate cancer. The scientists will evaluate whether the vaccine leads to a change in prostate cancer progression compared to patients on active surveillance, in which disease progression is monitored before other strategies, such as surgery or radiotherapy, are considered. PSA doubling time – the time needed for blood levels of PSA to double, considered a predictor of cancer progression and survival – and adverse events will also be assessed. Treatment-arm patients will be start with a four-month induction period,  being given six doses of ProscaVax at weeks 1, 2, 3, 7, 11 and 15. This period will be followed by maintenance injections once every month, and alternating between low-dose IL-2 alone and the ProscaVax vaccine for six months. The single-site trial, which is expected to finish in August 2022, will be conducted at Beth Israel Deaconess Medical Center in Boston, and includes the Dana-Farber Cancer Institute. Patient
Subscribe or to access all post and page content.

Tagged , , , .

José is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimer’s disease.

Leave a Comment

Your email address will not be published. Required fields are marked *